Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flow cytometry crossmatching: an update.

G Y Terashita

    Clinical Transplants
    |January 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    The T-cell flow cytometry crossmatch (T-FCXM) is effective for sensitized transplant patients but less so for nonsensitized groups. Optimizing its use, especially for sensitized patients, can significantly improve kidney transplant outcomes and reduce nonfunction.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Platelet crossmatching for kidney transplants by flow cytometry.

    Transplantation·1989
    Same author

    Crossmatching on platelets by flow cytometry.

    Clinical transplants·1988
    Same author

    Flow cytometry crossmatching in human cadaver kidney transplantation.

    Transplantation proceedings·1987
    Same author

    Original disease of the recipient.

    Clinical transplants·1987
    Same author

    Detection of tumor-associated antigens in the sera of lung cancer patients by three monoclonal antibodies.

    Cancer research·1985
    Same author

    Sialosylated Lewisx in the sera of cancer patients detected by a cell-binding inhibition assay.

    Cancer research·1985

    Area of Science:

    • Transplantation immunology
    • Clinical immunology
    • Nephrology

    Background:

    • The T-cell flow cytometry crossmatch (T-FCXM) is a critical pre-transplant assessment.
    • Its effectiveness varies between sensitized and nonsensitized patient groups.
    • Understanding crossmatch performance is vital for optimizing renal transplant outcomes.

    Purpose of the Study:

    • To evaluate the effectiveness of T-cell flow cytometry crossmatch (T-FCXM) in different patient populations.
    • To assess the impact of T-FCXM reaction levels on post-transplant kidney function.
    • To compare the performance of T-FCXM and platelet FCXM (PL-FCXM) and explore their combined utility.

    Main Methods:

    • Prospective data analysis of T-cell flow cytometry crossmatch (T-FCXM) results.

    Related Experiment Videos

  • Correlation of T-FCXM reaction levels (channels) with kidney nonfunction and delayed graft function.
  • Comparative analysis of T-FCXM and platelet FCXM (PL-FCXM) sensitivity and specificity.

    • Main Results:

    • T-FCXM is effective for sensitized patients but less sensitive for nonsensitized groups.
    • T-FCXM reactions >10 channels correlate with 1-month kidney nonfunction.
    • Higher T-FCXM reactions (>20 channels) are linked to delayed kidney function.
    • Raising the T-FCXM threshold to 20 channels yields performance similar to PL-FCXM.
    • Combining T-FCXM and PL-FCXM reduces false positives, enhancing overall utility.

    Conclusions:

    • Full implementation of T-FCXM for sensitized patients can prevent more cases of nonfunctioning transplanted kidneys.
    • Optimizing T-FCXM protocols and thresholds can significantly improve renal transplant success rates.
    • Further integration of FCXM techniques, including PL-FCXM, is recommended to enhance transplant outcomes.